All In Biotech

Drug Trial Radar · NCT00509795

Vascular Endothelial Growth Factor VEGF Trap-Eye:Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration(AMD)

A Randomized, Double Masked, Active Controlled Phase III Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal VEGF Trap in Subjects With Neovascular Age-Related Macular Degeneration

Last checked: Nov 20, 2026Latest source record: Dec 28, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,217 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,217

Actual

Start

Aug 2007

Primary completion

Sep 2010

Study completion Jul 2011

Sponsor

Lead sponsor
Regeneron PharmaceuticalsRegeneron (REGN)
Sponsor type
Industry
Collaborators
Bayer
First posted
Aug 1, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a phase 3, double-masked, randomized, study of the efficacy and safety of VEGF Trap-Eye in patients with neovascular age-related macular degeneration. Approximately 1200 patients will be randomized in the US and Canada.

Conditions

  • Macular Degeneration

Interventions

  • ranibizumabBiological

    Participants received a 0.5mg dose of ranibizumab via intravitreal (IVT) injection every 4 weeks for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.

  • aflibercept injection (VEGF Trap-Eye, BAY86-5321)Biological

    Participants received a 2.0mg dose of aflibercept injection every 4 weeks for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.

  • aflibercept injection (VEGF Trap-Eye, BAY86-5321)Biological

    Participants received a 0.5mg dose of aflibercept injection every 4 weeks for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.

  • aflibercept injection (VEGF Trap-Eye, BAY86-5321)Biological

    Participants received a 2.0mg dose of aflibercept injection every 8 weeks (including one additional 2.0 mg dose at Week 4) for the first year and were to receive sham injections at interim monthly visits. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Patients Who Maintained Vision at Week 52 - Last Observation Carried Forward (LOCF)Time frame: Baseline and at week 52

Locations

188 sites in 2 countries. Site status is shown where the registry gives one.

  • Site not named

    Birmingham, Alabama

  • Site not named

    Birmingham, Alabama

  • Site not named

    Phoenix, Arizona

  • Site not named

    Phoenix, Arizona

  • Site not named

    Tucson, Arizona

  • Site not named

    Tucson, Arizona

  • Site not named

    Beverly Hills, California

  • Site not named

    Campbell, California

  • Site not named

    Fullerton, California

  • Site not named

    Glendale, California

  • Site not named

    Irvine, California

  • Site not named

    La Jolla, California

  • Site not named

    Loma Linda, California

  • Site not named

    Los Angeles, California

  • Site not named

    Los Angeles, California

  • Site not named

    Menlo Park, California

  • Site not named

    Mountain View, California

  • Site not named

    Oakland, California

  • Site not named

    Palm Springs, California

  • Site not named

    Pasadena, California

  • Site not named

    Poway, California

  • Site not named

    Sacramento, California

  • Site not named

    San Diego, California

  • Site not named

    San Francisco, California

  • Site not named

    Santa Ana, California

  • Site not named

    Torrance, California

  • Site not named

    Ventura, California

  • Site not named

    Westlake Village, California

  • Site not named

    Yorba Linda, California

  • Site not named

    Aurora, Colorado

  • Site not named

    Denver, Colorado

  • Site not named

    Denver, Colorado

  • Site not named

    Bridgeport, Connecticut

  • Site not named

    Hamden, Connecticut

  • Site not named

    New Haven, Connecticut

  • Site not named

    New London, Connecticut

  • Site not named

    Altamonte Springs, Florida

  • Site not named

    Boynton Beach, Florida

  • Site not named

    Fort Lauderdale, Florida

  • Site not named

    Fort Myers, Florida

Showing 40 of 188 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.